<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00467493</url>
  </required_header>
  <id_info>
    <org_study_id>M-001</org_study_id>
    <nct_id>NCT00467493</nct_id>
  </id_info>
  <brief_title>Partial Double-Blind, Placebo-Controlled Study to Assess the Effect of Anastrozole on the Endometrium in Healthy Volunteers</brief_title>
  <official_title>A Partial Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Anastrozole, an Aromatase Inhibitor, on Endometrial Thickness in Healthy Premenopausal Women When Dosed at Various Times During the Menstrual Cycle (Protocol M-001)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Meditrina Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Meditrina Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aromatase inhibitors have been approved for use in postmenopausal women to treat and prevent&#xD;
      breast cancer. They act by blocking the action of the enzyme, aromatase, that is necessary&#xD;
      for the production of estradiol. This class of drugs, aromatase inhibitors, are very&#xD;
      effective in reducing estradiol levels in postmenopausal women and in treating estrogen&#xD;
      receptor positive breast cancers. This study is examining the effect of a specific inhibitor,&#xD;
      anastrozole, on endometrial thickness in premenopausal women. The endometrium is sensitive to&#xD;
      estradiol and also has local aromatase which, if inhibited, may result in reduced endometrial&#xD;
      thickness. The main hypothesis is that anastrozole can be administered at any time during the&#xD;
      menstrual cycle and reduce endometrial thickness compared to placebo.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">September 2007</completion_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endometrial thickness as measured by transvaginal ultrasound, safety</measure>
    <time_frame>Over one menstrual cycle</time_frame>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Menstruation Disorders</condition>
  <arm_group>
    <arm_group_label>Anastrozole - A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment for 26 consecutive days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anastrozole -B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment for 7 consecutive days early in menstrual cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anastrozoe - C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment for 7 consecutive days mid follicular phase</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anastrozole - D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment for 7 consecutive days - mid cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anastrozole - E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment for 7 consecutive days - luteal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anastrozole - F</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Treatment with placebo for 26 consecutive days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anastrozole</intervention_name>
    <arm_group_label>Anastrozoe - C</arm_group_label>
    <arm_group_label>Anastrozole - A</arm_group_label>
    <arm_group_label>Anastrozole - D</arm_group_label>
    <arm_group_label>Anastrozole - E</arm_group_label>
    <arm_group_label>Anastrozole - F</arm_group_label>
    <arm_group_label>Anastrozole -B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Between the ages of 25 and 45 and pre-menopausal;&#xD;
&#xD;
          -  Non-lactating and not pregnant&#xD;
&#xD;
          -  able to follow the schedule of procedures&#xD;
&#xD;
          -  able to freely provide informed consent&#xD;
&#xD;
          -  have clinically acceptable physical examination and safety laboratory studies&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  current use of any form of systemic contraceptive&#xD;
&#xD;
          -  have self-reported irregular menstrual cycles&#xD;
&#xD;
          -  intercurrent illness(es) detected on the screening physical&#xD;
&#xD;
          -  unwilling or unable to use barrier methods of contraception&#xD;
&#xD;
          -  have evidence of endometrial polyps or myomata on TVU/SIS that would interfere with&#xD;
             endometrial thickness measurement&#xD;
&#xD;
          -  detection of ovarian cyst(s) during adnexal examination on screening TVU/SIS measuring&#xD;
             greater than 5 cm&#xD;
&#xD;
          -  have history of, or current cancer, on any form exclusive of basal cell carcinoma&#xD;
&#xD;
          -  BMI &gt;= 35&#xD;
&#xD;
          -  history of alcohol or drug abuse in the past 5 years&#xD;
&#xD;
          -  unwilling or unable to undergo study procedures within the necessary time frames&#xD;
&#xD;
          -  history or current liver abnormalities as defined by ALT or AST &gt; 2X ULN&#xD;
&#xD;
          -  treated or untreated diabetes defined as fasting blood sugar &gt;= 126 mg/dL&#xD;
&#xD;
          -  untreated hypertension&#xD;
&#xD;
          -  impaired renal function by estimated creatinine clearance &lt; 80mL/min&#xD;
&#xD;
          -  have estradiol levels &lt; 20 pg/ml and FSH levels &gt; 40 mIU/mL or&#xD;
&#xD;
          -  have a history of adverse reaction any aromatase inhibitor&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Jasper Research Clinic</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Women's Care</name>
      <address>
        <city>Southfield</city>
        <state>Michigan</state>
        <zip>48034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <study_first_submitted>April 27, 2007</study_first_submitted>
  <study_first_submitted_qc>April 27, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 30, 2007</study_first_posted>
  <last_update_submitted>June 2, 2009</last_update_submitted>
  <last_update_submitted_qc>June 2, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2009</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Menstruation Disturbances</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anastrozole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

